Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (6): 1139-1143. doi: 10.19723/j.issn.1671-167X.2023.06.029

Previous Articles     Next Articles

情怡 卢, 艾尼扎提·哈斯木,宇菲 李,春 李*()   

  • Received:2023-08-22 Online:2023-12-18 Published:2023-12-11
  • Contact: 春 李 E-mail:fiona_leechun@163.com
  • Supported by:
    Beijing Municipal Science and Technology Projects(Z191100006619110);China International Medical Foundation(Z-2018-40-2101)

RICH HTML

   

PDF (PC)

CLC Number: 

  • R593.2

Table 1

Demographics characteristics of APS patients(n=141)"

Parameters Data
Age/years 45.4±15.8
Female 92/141 (65.2)
Thrombosis 94/141 (66.7)
Venous thrombosis 55/141 (39.0)
Arterial thrombosis 52/141 (36.9)
Both venous and arterial thrombosis 16/141 (11.3)
Pregnancy morbidity 45/141 (31.9)
Both thrombosis and pregnancy morbidity 7/141 (5.0)
Thrombocytopenia 33 /121(23.4)
aCL antibody (+) 36/132 (27.3)
αβ2GPⅠ antibody (+) 61/133 (45.9)
LAC (+) 55/126 (43.7)
Double positive aPL 7/126 (5.5)
Triple positive aPL 22/126 (17.5)
Triple negative aPL 36/126 (28.6)

Figure 1

Titers (A) and positive rate (B) of Ceramide-Ab in APS patients, disease controls, and healthy controls *P < 0.05, **P < 0.01. APS, antiphospholipid syndrome; HC, healthy controls; DC, disease controls; Ceramide-Ab, anti-ceramide antibody."

Table 2

The relationship between Ceramide-Ab and clinical symptoms and laboratory parameters in APS patients"

Parameters Ceramide-Ab(+) Ceramide-Ab(-) P
Primary APS 23/35 (65.7) 78/106 (73.6) 0.370
Hyperlipidemia 2/35 (5.7) 23/106 (21.7) 0.032
Hypertension 17/35 (48.6) 21/106 (19.8) 0.001
Diabetes 5/35 (14.3) 10/106 (9.4) 0.420
Coronary heart disease 6/35 (17.1) 6/106 (5.7) 0.035
Thrombosis 28/35 (80.0) 66/106 (62.3) 0.054
Arterial thrombosis 11/35 (31.4) 41/106 (38.7) 0.441
Venous thrombosis 20/35 (57.1) 35/106 (33.0) 0.011
Both arterial and venous thrombosis 3/35 (8.6) 13/106 (12.3) 0.550
Pregnancy morbidity 8/35 (22.9) 37/106 (34.9) 0.185
Both thrombosis and pregnancy morbidity 3/35 (8.6) 4/106 (3.8) 0.257
Anemia 10/31 (32.3) 28/90 (31.1) 0.906
Thrombocytopenia 11/31 (35.5) 22/90 (24.4) 0.234
aCL(+) 12/33 (36.4) 24/99 (24.2) 0.176
aβ2GPⅠ(+) 17/33 (51.5) 44/100 (44.0) 0.452
LAC(+) 13/32 (40.6) 42/94 (44.7) 0.689
Double positive aPL 0 7/94 (7.4) 0.112
Triple positive aPL 6/32 (18.8) 16/93 (17.2) 0.843
Hypocomplementemia* 1/24 (4.2) 12/66 (18.2) 0.094
aGAPSS 6.00±4.64 5.75±4.90 0.587

Figure 2

ROC curve of anti-ceramide antibody in the diagnosis of APS"

Table 3

Sensitivity, specificity and Youden index of anti-ceramide antibody in APS patients with negative aPL antibodies"

Negative antibody Sensitivity Specificity Youden index
LAC 0.268 0.944 0.212
aCL 0.219 0.944 0.163
aβ2GPⅠ 0.222 0.944 0.166
aCL+ aβ2GPⅠ 0.215 0.944 0.159
aβ2GPⅠ+LAC 0.225 0.944 0.169
aCL+LAC 0.233 0.944 0.177
aCL+aβ2GPⅠ+LAC 0.194 0.944 0.138
1 Garcia D , Erkan D . Diagnosis and management of the antiphospholipid syndrome[J]. N Engl J Med, 2018, 378 (21): 2010- 2021.
doi: 10.1056/NEJMra1705454
2 Miyakis S , Lockshin MD , Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4 (2): 295- 306.
doi: 10.1111/j.1538-7836.2006.01753.x
3 Hughes GR , Khamashta MA . Seronegative antiphospholipid syndrome[J]. Ann Rheum Dis, 2003, 62 (12): 1127.
doi: 10.1136/ard.2003.006163
4 Zietzer A , Düsing P , Reese L , et al. Ceramide metabolism in cardiovascular disease: A network with high therapeutic potential[J]. Arterioscler Thromb Vasc Biol, 2022, 42 (10): 1220- 1228.
doi: 10.1161/ATVBAHA.122.318048
5 Yuan H , Zhu B , Li C , et al. Ceramide in cerebrovascular diseases[J]. Front Cell Neurosci, 2023, 17, 1191609.
doi: 10.3389/fncel.2023.1191609
6 Shu H , Peng Y , Hang W , et al. Emerging roles of ceramide in cardiovascular diseases[J]. Aging Dis, 2022, 13 (1): 232- 245.
doi: 10.14336/AD.2021.0710
7 Alexandropoulou I , Grammatikopoulou MG , Gkouskou KK , et al. Ceramides in autoimmune rheumatic diseases: Existing evidence and therapeutic considerations for diet as an anticeramide treatment[J]. Nutrients, 2023, 15 (1): 229.
doi: 10.3390/nu15010229
8 Radin M , Sciascia S , Erkan D , et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort[J]. Semin Arthritis Rheum, 2019, 49 (3): 464- 468.
doi: 10.1016/j.semarthrit.2019.04.009
9 Yin W , Li F , Tan X , et al. Plasma ceramides and cardiovascular events in hypertensive patients at high cardiovascular risk[J]. Am J Hypertens, 2021, 34 (11): 1209- 1216.
doi: 10.1093/ajh/hpab105
10 张鹏, 陈夏欢, 王昊, 等. 神经酰胺在心血管疾病预测价值中的研究进展[J]. 中国心血管杂志, 2020, 25 (2): 189- 192.
11 Bismuth J , Lin P , Yao Q , et al. Ceramide: A common pathway for atherosclerosis?[J]. Atherosclerosis, 2008, 196 (2): 497- 504.
doi: 10.1016/j.atherosclerosis.2007.09.018
12 Hamada Y , Nagasaki H , Fujiya A , et al. Involvement of de novo ceramide synthesis in pro-inflammatory adipokine secretion and adipocyte-macrophage interaction[J]. J Nutr Biochem, 2014, 25 (12): 1309- 1316.
doi: 10.1016/j.jnutbio.2014.07.008
13 Laaksonen R , Ekroos K , Sysi-Aho M , et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J, 2016, 37 (25): 1967- 1976.
doi: 10.1093/eurheartj/ehw148
14 Vasile VC , Meeusen JW , Medina Inojosa JR , et al. Ceramide scores predict cardiovascular risk in the community[J]. Arterioscler Thromb Vasc Biol, 2021, 41 (4): 1558- 1569.
doi: 10.1161/ATVBAHA.120.315530
15 Chen WF , Lee JJ , Chang CC , et al. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets[J]. Haematologica, 2013, 98 (5): 793- 801.
doi: 10.3324/haematol.2012.072553
16 Pignatelli P , Ettorre E , Menichelli D , et al. Seronegative antiphospholipid syndrome: Refining the value of "non-criteria" antibodies for diagnosis and clinical management[J]. Haematologica, 2020, 105 (3): 562- 572.
doi: 10.3324/haematol.2019.221945
17 Zhang S , Wu Z , Zhang W , et al. Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome[J]. Clin Chim Acta, 2019, 495, 205- 209.
doi: 10.1016/j.cca.2019.04.065
18 Lopez LR , Dier KJ , Lopez D , et al. Anti-beta 2-glycoprotein Ⅰ and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome[J]. Am J Clin Pathol, 2004, 121 (1): 142- 149.
doi: 10.1309/YVQ6PX76XMYM3J29
19 Castanon A , Pierre G , Willis R , et al. Performance evaluation and clinical associations of immunoassays that detect antibodies to negatively charged phospholipids other than cardiolipin[J]. Am J Clin Pathol, 2018, 149 (5): 401- 411.
doi: 10.1093/ajcp/aqy003
20 Li S , Bai Y , Meng J , et al. Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients[J]. Front Immunol, 2023, 14, 1107510.
doi: 10.3389/fimmu.2023.1107510
21 Summers SA , Chaurasia B , Holland WL . Metabolic messengers: Ceramides[J]. Nat Metab, 2019, 1 (11): 1051- 1058.
doi: 10.1038/s42255-019-0134-8
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Jiyan CHU, Ping LI, Jing TIAN, Diyu FU, Lin GUO, Rui SUN, Yadi LI. Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 175-183.
[3] Yuan LIU, Guixiu SHI. Change from Sjögren syndrome to Sjögren disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1015-1017.
[4] Yirui LIAN, Jingxuan LIU, Liang ZHAO, Jing ZHAO, Sitian ZANG, Yuhui LI. Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1018-1023.
[5] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[6] Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041.
[7] Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[8] Yayun ZHAO, Mengfan NI, Xue LI, Bei WANG, Gong CHENG, Jing HE, Yuebo JIN. Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1051-1060.
[9] Jiajing PENG, Li CUI. Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1061-1066.
[10] Yajing GAO, Zhengfang LI, Mengsi MA, Lijun WU. Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1067-1073.
[11] Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[12] Xinfeng WU, Siliang MAN, Dazhao CHEN, Yong HUA, Xijie WEN, Yingyue DING, Liang ZHANG, Xiujuan HOU. A long-term review for radiographic parameters of hips in axial spondyloarthritis patients with end-stage hip involvement: A 24-year trend analysis from a single high-volume tertiary center [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1089-1095.
[13] Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106.
[14] Yanyan LI, Xiangjun LIU, Gongming LI, Chun LI, Yuan JIA. Clinic behavior and therapeutic status of patients with antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1107-1112.
[15] Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd